Teva Pharmaceutical Industries Ltd. $TEVA is Mangrove Partners IM LLC’s 8th Largest Position

Mangrove Partners IM LLC increased its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 21.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,338,237 shares of the company’s stock after buying an additional 405,810 shares during the quarter. Teva Pharmaceutical Industries accounts for 3.9% of Mangrove Partners IM LLC’s portfolio, making the stock its 8th largest position. Mangrove Partners IM LLC owned about 0.20% of Teva Pharmaceutical Industries worth $47,232,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Cromwell Holdings LLC boosted its holdings in Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after acquiring an additional 629 shares in the last quarter. Advisors Asset Management Inc. bought a new position in Teva Pharmaceutical Industries in the 2nd quarter worth $41,000. Rothschild Investment LLC lifted its position in shares of Teva Pharmaceutical Industries by 97.0% in the 3rd quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock worth $55,000 after purchasing an additional 1,348 shares during the period. JFS Wealth Advisors LLC lifted its position in shares of Teva Pharmaceutical Industries by 257.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 2,778 shares of the company’s stock worth $56,000 after purchasing an additional 2,000 shares during the period. Finally, LRI Investments LLC boosted its stake in shares of Teva Pharmaceutical Industries by 246.0% during the 3rd quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock valued at $57,000 after purchasing an additional 2,000 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors.

Insider Transactions at Teva Pharmaceutical Industries

In other news, CEO Richard D. Francis sold 442,935 shares of the business’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $32.36, for a total value of $14,333,376.60. Following the completion of the transaction, the chief executive officer owned 642,099 shares in the company, valued at $20,778,323.64. The trade was a 40.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Richard Daniell sold 17,295 shares of the stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $547,732.65. Following the sale, the executive vice president directly owned 85,755 shares in the company, valued at $2,715,860.85. This trade represents a 16.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 948,499 shares of company stock valued at $30,897,071. Insiders own 0.49% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on TEVA shares. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Scotiabank lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. Jefferies Financial Group upped their target price on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Barclays increased their target price on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Finally, Truist Financial lifted their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

Teva Pharmaceutical Industries Trading Down 2.6%

NYSE:TEVA opened at $28.54 on Friday. The company’s 50 day moving average price is $32.91 and its 200-day moving average price is $26.62. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $37.35. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The stock has a market cap of $32.81 billion, a price-to-earnings ratio of 23.78, a PEG ratio of 9.81 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.31. The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the previous year, the business earned $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.